Aflibercept

Aflibercept
Clinical data
Trade namesEylea, Zaltrap
Other namesziv-aflibercept
Biosimilarsaflibercept-abzv,[1][2] aflibercept-ayyh,[1][3] aflibercept-jbvf,[1][4] aflibercept-mrbb,[1][5] aflibercept-yszy,[1][6] Ahzantive,[1][5][7][8] Baiama,[9] Enzeevu,[1][2] Eydenzelt,[10] Opuviz,[1][6] Pavblu,[1][3] Yesafili[1][4][11][12]
AHFS/Drugs.com
MedlinePlusa612004
License data
Pregnancy
category
  • AU: D[13]
  • Not recommended
Routes of
administration		Intravenous, intravitreal injection
Drug classAntineovascularization agent
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC4318H6788N1164O1304S32
Molar mass96898.57 g·mol−1
 NY (what is this?)  (verify)

Aflibercept, sold under the brand names Eylea and Zaltrap among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer.[18][19] It was developed by Regeneron Pharmaceuticals.

It is an inhibitor of vascular endothelial growth factor (VEGF).[20][21] Aflibercept is a recombinant fusion protein consisting of the extracellular domains of human VEGF receptor 1 and 2 fused to the Fc portion of human IgG1.[22] By acting as a soluble decoy for the natural VEGF receptors, aflibercept inhibits their activation, thereby reducing angiogenesis.[22]

  1. ^ a b c d e f g h i j Cite error: The named reference Biosimilar Drug Information was invoked but never defined (see the help page).
  2. ^ a b Cite error: The named reference Enzeevu FDA label was invoked but never defined (see the help page).
  3. ^ a b Cite error: The named reference Pavblu FDA label was invoked but never defined (see the help page).
  4. ^ a b "Yesafili (aflibercept-jbvf) injection, for intravitreal use" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 21 May 2024. Retrieved 19 August 2024.
  5. ^ a b Cite error: The named reference Ahzantive FDA label was invoked but never defined (see the help page).
  6. ^ a b "Opuviz (aflibercept-yszy) injection, for intravitreal use" (PDF). Archived from the original (PDF) on 21 May 2024. Retrieved 21 May 2024.
  7. ^ Cite error: The named reference Ahzantive EPAR was invoked but never defined (see the help page).
  8. ^ Cite error: The named reference Ahzantive PI was invoked but never defined (see the help page).
  9. ^ Cite error: The named reference Baiama EPAR was invoked but never defined (see the help page).
  10. ^ "Eydenzelt (Celltrion Healthcare Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 16 April 2025. Retrieved 3 May 2025.
  11. ^ Cite error: The named reference Yesafili EPAR was invoked but never defined (see the help page).
  12. ^ "Yesafili Product information". Union Register of medicinal products. 19 September 2023. Archived from the original on 2 October 2023. Retrieved 2 October 2023.
  13. ^ "Ziv-aflibercept (Zaltrap) Use During Pregnancy". Drugs.com. 25 December 2019. Archived from the original on 29 November 2020. Retrieved 12 March 2020.
  14. ^ "Regulatory Decision Summary for Eylea HD". Drug and Health Products Portal. 2 February 2024. Archived from the original on 2 April 2024. Retrieved 2 April 2024.
  15. ^ Cite error: The named reference Eylea FDA label was invoked but never defined (see the help page).
  16. ^ Cite error: The named reference Zaltrap FDA label was invoked but never defined (see the help page).
  17. ^ "Eylea HD- aflibercept injection, solution". DailyMed. 18 August 2023. Archived from the original on 29 August 2023. Retrieved 28 August 2023.
  18. ^ a b "Eylea EPAR". European Medicines Agency (EMA). 9 July 2019. Archived from the original on 9 November 2020. Retrieved 12 March 2020.
  19. ^ a b "Zaltrap EPAR". European Medicines Agency (EMA). 12 November 2019. Archived from the original on 11 November 2020. Retrieved 12 March 2020.
  20. ^ Fraser HM, Wilson H, Silvestri A, Morris KD, Wiegand SJ (September 2008). "The role of vascular endothelial growth factor and estradiol in the regulation of endometrial angiogenesis and cell proliferation in the marmoset". Endocrinology. 149 (9): 4413–20. doi:10.1210/en.2008-0325. PMID 18499749. Archived from the original on 8 December 2019. Retrieved 3 July 2008.
  21. ^ Duncan WC, van den Driesche S, Fraser HM (July 2008). "Inhibition of vascular endothelial growth factor in the primate ovary up-regulates hypoxia-inducible factor-1alpha in the follicle and corpus luteum". Endocrinology. 149 (7): 3313–20. doi:10.1210/en.2007-1649. PMID 18388198.
  22. ^ a b Cite error: The named reference Eydenzelt EPAR was invoked but never defined (see the help page).
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.